• Home
  • Feasibility and Safety of Intratympanic Administration of Sustained-Exposure Dexamethasone Thermosensitive Gel (OTO-104) for Prevention of Cisplatin-Induced Hearing Loss in Children: A Multisite Phase 2 Randomized Clinical Trial.

Feasibility and Safety of Intratympanic Administration of Sustained-Exposure Dexamethasone Thermosensitive Gel (OTO-104) for Prevention of Cisplatin-Induced Hearing Loss in Children: A Multisite Phase 2 Randomized Clinical Trial.

Author List
Freyer DR, Ohlsen TJD, Don D, Orgel E, Hayashi RJ, Lieu JE, Foster JH, Sitton MS, Geller JI, Choo DI, Rangaswami A, Chang KW, Greffe B, Chan K, Lee A, Grunstein E, O'Neill AF, Rahbar R, Anderson JJ
Publication
Pediatric blood & cancer
Publication ID (Profile URL)
https://researcherprofiles.org/profile/613166540
Publication Year
2025
PubMed ID
40128126
Publication Title
Freyer DR, Ohlsen TJD, Don D, Orgel E, Hayashi RJ, Lieu JE, Foster JH, Sitton MS, Geller JI, Choo DI, Rangaswami A, Chang KW, Greffe B, Chan K, Lee A, Grunstein E, O'Neill AF, Rahbar R, Anderson JJ. Feasibility and Safety of Intratympanic Administration of Sustained-Exposure Dexamethasone Thermosensitive Gel (OTO-104) for Prevention of Cisplatin-Induced Hearing Loss in Children: A Multisite Phase 2 Randomized Clinical Trial. Pediatr Blood Cancer. 2025 Jun; 72(6):e31680.